311 related articles for article (PubMed ID: 29724397)
1. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
9. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
11. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
12. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
14. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
[TBL] [Abstract][Full Text] [Related]
17. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
